Previous 10 | Next 10 |
Natesto Spermatogenesis Study Data Readout Set for October 16, 2019 ENGLEWOOD, CO / ACCESSWIRE / August 1, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs,...
Sigma Labs (NASDAQ: SGLB ) +19% to work with airbus to deploy PrintRite3D rapid test and evaluation program More news on: Sigma Labs, Inc., Valeritas Holdings, Inc., RingCentral, Inc., Stocks on the move, Read more ...
Thinly traded nano cap Aytu BioScience (NASDAQ: AYTU ) is up 9% premarket on modestly higher volume in reaction to its expanded agreement with commercialization partner Acerus Pharmaceuticals ( OTCQB:ASPCF ). More news on: Aytu BioScience, Inc., Acerus Pharmaceuticals Corpora...
TORONTO , July 30, 2019 /PRNewswire/ -- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB: ASPCF) today announced that it will be taking an expanded role in the commercialization of NATESTO ® in the U.S. The company has entered into an amended and restated licensing agreement ...
Acerus to Launch U.S. Specialty Sales Force; Nearly Doubles Natesto Sales Force ENGLEWOOD, CO / ACCESSWIRE / July 30, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant p...
ENGLEWOOD, CO / ACCESSWIRE / July 24, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced that Natesto ® (testosterone nasal gel) is now on formula...
Oasmia Pharmaceutical AB (NASDAQ: OASM ) +22% . More news on: Oasmia Pharmaceutical AB (publ), Sangamo Therapeutics, Inc., Aytu BioScience, Inc., Stocks on the move, Read more ...
Aytu BioScience's (NASDAQ: AYTU ) study titled, Efficacy of Nasal Testosterone Gel (Natesto) Stratified by Baseline Endogenous Testosterone Levels, achieves similar symptom improvement , regardless of the degree of patients’ testosterone deficiency, while maintaining function of...
First Natesto Study to Demonstrate Efficacy in Severely Hypogonadal Patients ENGLEWOOD, CO / ACCESSWIRE / July 8, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced t...
ENGLEWOOD, CO / ACCESSWIRE / July 1, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced that it has been added to the Russell Microcap® Index effective after the U.S....
News, Short Squeeze, Breakout and More Instantly...
Company receives proceeds of $3.5 million through exercise of warrants, a portion of which was used to pay down debt Interest rate on new $13.0 million term loan reduced by approximately 350 basis points today, potentially saving the Company $1.3 million over the life of the term loan T...
Phoenix, Arizona and New York, New York--(Newsfile Corp. - May 29, 2024) - Lytham Partners, a leading investor relations and corporate access firm, today announced the schedule for its Spring 2024 Investor Conference taking place virtually on May 30, 2024. More than 40 companies will be available...
DENVER, CO / ACCESSWIRE / May 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a webcasted fireside chat and host one-on-one meetings with inv...